NHC director receives 7,500 stock options grant
NATIONAL HEALTHCARE CORP director James Paul Abernathy reported an equity award and updated holdings.
Rhea-AI Filing Summary
NATIONAL HEALTHCARE CORP director James Paul Abernathy reported an equity award and updated holdings. He received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2031. The options were granted under the 2020 Omnibus Equity Incentive Plan and are described as exempt from Section 16(b) under Rule 16b-3(d).
Following the reported entries, he directly holds 43,302 shares of common stock. He also holds previously granted options covering 7,500 shares at $94.66, 7,500 shares at $96.03, and 4,360 shares at $55.75, providing additional potential future share exposure if exercised.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 7,500 shares
Grant/Award
5 txns
Insider
ABERNATHY JAMES PAUL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock [2026 Grant] | 7,500 | $0.00 | $0.00 |
| holding | Option to Purchase Common Stock [2023 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2024 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2025 Grant] | -- | -- | -- |
| holding | Shares of Common Stock | -- | -- | -- |
Holdings After Transaction:
Option to Purchase Common Stock [2026 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2023 Grant] — 4,360 contracts (Direct);
Option to Purchase Common Stock [2024 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2025 Grant] — 7,500 contracts (Direct);
Shares of Common Stock — 43,302 shares (Direct)
Footnotes (1)
- F1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
Key Figures
Direct common shares held: 43,302 shares
2026 option grant size: 7,500 shares
2026 grant exercise price: $171.42 per share
+4 more
7 metrics
Direct common shares held
43,302 shares
Shares of Common Stock held directly after reported transactions
2026 option grant size
7,500 shares
Option to purchase common stock [2026 Grant] underlying shares
2026 grant exercise price
$171.42 per share
Conversion or exercise price for 2026 option grant
2026 grant expiration
May 6, 2031
Expiration date of 2026 option grant
2025 option grant
7,500 shares at $94.66
Underlying shares and exercise price, expiration May 7, 2030
2024 option grant
7,500 shares at $96.03
Underlying shares and exercise price, expiration May 8, 2029
2023 option grant
4,360 shares at $55.75
Underlying shares and exercise price, expiration May 3, 2028
Key Terms
Option to Purchase Common Stock, 2020 Omnibus Equity Incentive Plan, Section 16(b), Rule 16b-3(d), +1 more
5 terms
Option to Purchase Common Stock financial
"security_title: "Option to Purchase Common Stock [2026 Grant]""
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan"
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"exempt from Section 16(b) pursuant to Rule 16b-3(d)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NHC director James Paul Abernathy report in this Form 4?
He reported an equity award and his updated holdings. Abernathy received an option for 7,500 NATIONAL HEALTHCARE CORP shares and disclosed that he now directly holds 43,302 common shares, plus several existing option grants with different exercise prices and expiration dates.
What are the key terms of Abernathy’s 2026 stock option grant at NHC?
The 2026 grant covers options on 7,500 NATIONAL HEALTHCARE CORP shares with a $171.42 exercise price. These options were granted under the 2020 Omnibus Equity Incentive Plan and expire on May 6, 2031, giving a multi‑year window during which Abernathy can choose to exercise.
What other stock options does Abernathy hold in NATIONAL HEALTHCARE CORP?
He holds options from prior grants covering 7,500 shares at $94.66, 7,500 shares at $96.03, and 4,360 shares at $55.75. These options have expiration dates between 2028 and 2030, representing additional potential ownership if exercised over time.
Under what plan were Abernathy’s new NHC options granted?
The new options were granted under the 2020 Omnibus Equity Incentive Plan. The filing notes the grant and potential exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d), indicating they are structured as board‑approved compensation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
